Is PSMA PET disrupting traditional prostate cancer staging and treatment?
Can J Urol. 2024 Apr;31(2):11814-11815.NO ABSTRACTPMID:38642457 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - April 20, 2024 Category: Urology & Nephrology Authors: Leonard G Gomella Source Type: research
Holmium laser enucleation of the prostate for a case of transition zone prostate cancer
We present a case of transition zone prostate cancer that was treated with holmium laser enucleation of the prostate, a procedure that is normally reserved for the management of benign prostatic hyperplasia.PMID:38642466 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - April 20, 2024 Category: Urology & Nephrology Authors: Michelle K Li Orlando Diaz Jonathan E Katz Source Type: research
Is PSMA PET disrupting traditional prostate cancer staging and treatment?
Can J Urol. 2024 Apr;31(2):11814-11815.NO ABSTRACTPMID:38642457 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - April 20, 2024 Category: Urology & Nephrology Authors: Leonard G Gomella Source Type: research
Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways
CONCLUSIONS: Prostate cancer patients receiving ADT with or without ATT need to be more zealously assessed for prevention and aggressively managed to reduce cardiovascular events. This can and should include participation from the entire multidisciplinary healthcare team.PMID:38642459 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - April 20, 2024 Category: Urology & Nephrology Authors: David E Crawford David Albala Marc B Garnick Andrew W Hahn Paul Maroni Rana R McKay Martin Miner Peter Orio Ⅲ Kshitij Pandit Scott Sellinger Evan Y Yu Robert H Eckel Source Type: research
Holmium laser enucleation of the prostate for a case of transition zone prostate cancer
We present a case of transition zone prostate cancer that was treated with holmium laser enucleation of the prostate, a procedure that is normally reserved for the management of benign prostatic hyperplasia.PMID:38642466 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - April 20, 2024 Category: Urology & Nephrology Authors: Michelle K Li Orlando Diaz Jonathan E Katz Source Type: research
Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways
CONCLUSIONS: Prostate cancer patients receiving ADT with or without ATT need to be more zealously assessed for prevention and aggressively managed to reduce cardiovascular events. This can and should include participation from the entire multidisciplinary healthcare team.PMID:38642459 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - April 20, 2024 Category: Urology & Nephrology Authors: David E Crawford David Albala Marc B Garnick Andrew W Hahn Paul Maroni Rana R McKay Martin Miner Peter Orio Ⅲ Kshitij Pandit Scott Sellinger Evan Y Yu Robert H Eckel Source Type: research
Is PSMA PET disrupting traditional prostate cancer staging and treatment?
Can J Urol. 2024 Apr;31(2):11814-11815.NO ABSTRACTPMID:38642457 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - April 20, 2024 Category: Urology & Nephrology Authors: Leonard G Gomella Source Type: research
Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways
CONCLUSIONS: Prostate cancer patients receiving ADT with or without ATT need to be more zealously assessed for prevention and aggressively managed to reduce cardiovascular events. This can and should include participation from the entire multidisciplinary healthcare team.PMID:38642459 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - April 20, 2024 Category: Urology & Nephrology Authors: David E Crawford David Albala Marc B Garnick Andrew W Hahn Paul Maroni Rana R McKay Martin Miner Peter Orio Ⅲ Kshitij Pandit Scott Sellinger Evan Y Yu Robert H Eckel Source Type: research
Holmium laser enucleation of the prostate for a case of transition zone prostate cancer
We present a case of transition zone prostate cancer that was treated with holmium laser enucleation of the prostate, a procedure that is normally reserved for the management of benign prostatic hyperplasia.PMID:38642466 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - April 20, 2024 Category: Urology & Nephrology Authors: Michelle K Li Orlando Diaz Jonathan E Katz Source Type: research
Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways
CONCLUSIONS: Prostate cancer patients receiving ADT with or without ATT need to be more zealously assessed for prevention and aggressively managed to reduce cardiovascular events. This can and should include participation from the entire multidisciplinary healthcare team.PMID:38642459 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - April 20, 2024 Category: Urology & Nephrology Authors: David E Crawford David Albala Marc B Garnick Andrew W Hahn Paul Maroni Rana R McKay Martin Miner Peter Orio Ⅲ Kshitij Pandit Scott Sellinger Evan Y Yu Robert H Eckel Source Type: research
Is PSMA PET disrupting traditional prostate cancer staging and treatment?
Can J Urol. 2024 Apr;31(2):11814-11815.NO ABSTRACTPMID:38642457 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - April 20, 2024 Category: Urology & Nephrology Authors: Leonard G Gomella Source Type: research
Holmium laser enucleation of the prostate for a case of transition zone prostate cancer
We present a case of transition zone prostate cancer that was treated with holmium laser enucleation of the prostate, a procedure that is normally reserved for the management of benign prostatic hyperplasia.PMID:38642466 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - April 20, 2024 Category: Urology & Nephrology Authors: Michelle K Li Orlando Diaz Jonathan E Katz Source Type: research
Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways
CONCLUSIONS: Prostate cancer patients receiving ADT with or without ATT need to be more zealously assessed for prevention and aggressively managed to reduce cardiovascular events. This can and should include participation from the entire multidisciplinary healthcare team.PMID:38642459 (Source: Canadian Journal of Urology)
Source: Canadian Journal of Urology - April 20, 2024 Category: Urology & Nephrology Authors: David E Crawford David Albala Marc B Garnick Andrew W Hahn Paul Maroni Rana R McKay Martin Miner Peter Orio Ⅲ Kshitij Pandit Scott Sellinger Evan Y Yu Robert H Eckel Source Type: research
